weekly chemotherapy for head and neck cancer

Comparative study of Locally Advanced Squamous Cell Carcinoma of Head and Neck with Weekly vs Three Weekly Docetaxel, Cisplatin, 5 Fluro-uracil (DCF) Induction Chemotherapy Regime.

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

CTRI

Registry ID

CTRI/2018/07/015114

Enrollment

Registered

2018-07-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Locally advanced squamous cell carcinoma of head and neck

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Treatment naive 2. ECOG PS less than 2 3. Histologically confirmed locally advanced 4. Squamous cell Cancer of Head and Neck.

Exclusion criteria

Exclusion criteria: 1. Previous chemotherapy 2. Other malignancies/metastasis (Nasopharynx Ca) 3. Pregnancy/lactation 4. Uncontrolled Co â?? morbidities 5. Recurrent SCC Cancer of Head and Neck.

Design outcomes

Primary

Measure	Time frame
To compare and assess clinical and radiological response following 3 cycles of weekly Vs three weekly DCF regimen in locally advanced HNSCC.Timepoint: Before chemotherapy and post chemotherapy after 3 cycles between two yrs period	—

Secondary

Measure	Time frame
To assess progression free survival and toxicities between weekly vs. three weekly DCF regimen in locally advanced HNSCC.Timepoint: 1. PFS - post 2 yrs 2. Toxicities - weekly post chemotherapy and three weekly post three weekly chemotherapy	—

Countries

India

Contacts

Public ContactDr Tousif imdad MD

health care global enterprises limited

devaletousif@gmail.com

Outcome results